Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Centanafadine in Children With ADHD
NCT05428033Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of centanafadine in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Attention-Deficit/Hyperactivity Disorder Rating Scale Version 5 at 6 weeks. Started Jul 2022; status: completed.
02
Drugs
centanafadine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05428033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05428033.